Published in Nat Genet on February 01, 2001
Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet (2001) 22.07
A novel class of small RNAs: tRNA-derived RNA fragments (tRFs). Genes Dev (2009) 5.04
tRNA biology charges to the front. Genes Dev (2010) 4.07
Inference on haplotype effects in case-control studies using unphased genotype data. Am J Hum Genet (2003) 3.74
Quantitative-trait homozygosity and association mapping and empirical genomewide significance in large, complex pedigrees: fasting serum-insulin level in the Hutterites. Am J Hum Genet (2002) 3.51
The genetic dissection of complex traits in a founder population. Am J Hum Genet (2001) 3.36
Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet (2002) 2.57
Graphical modeling of the joint distribution of alleles at associated loci. Am J Hum Genet (2004) 2.50
Comparison of microsatellites versus single-nucleotide polymorphisms in a genome linkage screen for prostate cancer-susceptibility Loci. Am J Hum Genet (2004) 2.31
A novel founder mutation in the RNASEL gene, 471delAAAG, is associated with prostate cancer in Ashkenazi Jews. Am J Hum Genet (2002) 2.24
HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG). Hum Genet (2012) 2.18
A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. Am J Hum Genet (2005) 1.96
Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet (2003) 1.96
Assigning a function to a conserved group of proteins: the tRNA 3'-processing enzymes. EMBO J (2002) 1.90
Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer. Am J Hum Genet (2002) 1.86
A candidate prostate cancer susceptibility gene encodes tRNA 3' processing endoribonuclease. Nucleic Acids Res (2003) 1.78
A flexible Bayesian framework for modeling haplotype association with disease, allowing for dominance effects of the underlying causative variants. Am J Hum Genet (2006) 1.70
Pooled genome linkage scan of aggressive prostate cancer: results from the International Consortium for Prostate Cancer Genetics. Hum Genet (2006) 1.70
Localization of a susceptibility gene for familial nonmedullary thyroid carcinoma to chromosome 2q21. Am J Hum Genet (2001) 1.68
Drosophila RNase Z processes mitochondrial and nuclear pre-tRNA 3' ends in vivo. Nucleic Acids Res (2004) 1.68
Transforming growth factor-β and the hallmarks of cancer. Cell Signal (2010) 1.66
A CPSF-73 homologue is required for cell cycle progression but not cell growth and interacts with a protein having features of CPSF-100. Mol Cell Biol (2005) 1.65
Artemis is a phosphorylation target of ATM and ATR and is involved in the G2/M DNA damage checkpoint response. Mol Cell Biol (2004) 1.63
Endonucleolytic processing of CCA-less tRNA precursors by RNase Z in Bacillus subtilis. EMBO J (2003) 1.62
The complexity of prostate cancer: genomic alterations and heterogeneity. Nat Rev Urol (2012) 1.59
CHEK2 variants associate with hereditary prostate cancer. Br J Cancer (2003) 1.54
Analysis of the RNASEL gene in familial and sporadic prostate cancer. Am J Hum Genet (2002) 1.41
tRNA fragments in human health and disease. FEBS Lett (2014) 1.41
The genetic epidemiology of prostate cancer and its clinical implications. Nat Rev Urol (2013) 1.39
Mitochondrial tRNA 3' end metabolism and human disease. Nucleic Acids Res (2004) 1.37
Evaluation of linkage and association of HPC2/ELAC2 in patients with familial or sporadic prostate cancer. Am J Hum Genet (2001) 1.32
Mutation screening and association study of RNASEL as a prostate cancer susceptibility gene. Br J Cancer (2005) 1.31
Simple methods for assessing haplotype-environment interactions in case-only and case-control studies. Genet Epidemiol (2007) 1.29
A compendium of human mitochondrial gene expression machinery with links to disease. Environ Mol Mutagen (2010) 1.26
HPC2 variants and screen-detected prostate cancer. Am J Hum Genet (2001) 1.20
Role of genetic polymorphisms of the RNASEL gene on familial prostate cancer risk in a Japanese population. Br J Cancer (2003) 1.19
Significant evidence for a heritable contribution to cancer predisposition: a review of cancer familiality by site. BMC Cancer (2012) 1.18
A genome screen of families with multiple cases of prostate cancer: evidence of genetic heterogeneity. Am J Hum Genet (2001) 1.16
3' processing of eukaryotic precursor tRNAs. Wiley Interdiscip Rev RNA (2012) 1.15
The N-terminal half-domain of the long form of tRNase Z is required for the RNase 65 activity. Nucleic Acids Res (2004) 1.11
Prostate cancer aggressiveness locus on chromosome 7q32-q33 identified by linkage and allelic imbalance studies. Neoplasia (2002) 1.11
Deficiency in SNM1 abolishes an early mitotic checkpoint induced by spindle stress. Mol Cell Biol (2004) 1.10
Confirmation of linkage of prostate cancer aggressiveness with chromosome 19q. Am J Hum Genet (2003) 1.10
A common nonsense mutation in EphB2 is associated with prostate cancer risk in African American men with a positive family history. J Med Genet (2005) 1.09
Interleukin-10 polymorphisms, cancer susceptibility and prognosis. Fam Cancer (2006) 1.08
Incorporating single-locus tests into haplotype cladistic analysis in case-control studies. PLoS Genet (2007) 1.08
hSnm1 colocalizes and physically associates with 53BP1 before and after DNA damage. Mol Cell Biol (2002) 1.07
Snm1-deficient mice exhibit accelerated tumorigenesis and susceptibility to infection. Mol Cell Biol (2005) 1.07
Familiality in brain tumors. Neurology (2008) 1.06
Nuclear-encoded factors involved in post-transcriptional processing and modification of mitochondrial tRNAs in human disease. Front Genet (2015) 1.05
Common sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Am J Hum Genet (2002) 1.05
Characterization of TRZ1, a yeast homolog of the human candidate prostate cancer susceptibility gene ELAC2 encoding tRNase Z. BMC Mol Biol (2005) 1.03
Mammalian SNM1 is required for genome stability. Mol Genet Metab (2008) 1.03
Common 8q24 sequence variations are associated with Asian Indian advanced prostate cancer risk. Cancer Epidemiol Biomarkers Prev (2008) 1.03
Optimization and characterization of tRNA-shRNA expression constructs. Nucleic Acids Res (2007) 1.02
Interaction among variant vascular endothelial growth factor (VEGF) and its receptor in relation to prostate cancer risk. Prostate (2010) 1.02
Meta-analysis of associations of the Ser217Leu and Ala541Thr variants in ELAC2 (HPC2) and prostate cancer. Am J Hum Genet (2002) 1.01
Single and multivariate associations of MSR1, ELAC2, and RNASEL with prostate cancer in an ethnic diverse cohort of men. Cancer Epidemiol Biomarkers Prev (2010) 0.98
A major locus for hereditary prostate cancer in Finland: localization by linkage disequilibrium of a haplotype in the HPCX region. Hum Genet (2005) 0.98
Prostate cancer risk-associated genetic markers and their potential clinical utility. Asian J Androl (2013) 0.97
Phosphodiesterase 11A (PDE11A) genetic variants may increase susceptibility to prostatic cancer. J Clin Endocrinol Metab (2010) 0.97
How do human cells react to the absence of mitochondrial DNA? PLoS One (2009) 0.97
Genetic polymorphisms and prostate cancer risk. World J Urol (2003) 0.96
Disease variants in genomes of 44 centenarians. Mol Genet Genomic Med (2014) 0.96
Genome-wide linkage scan for prostate cancer susceptibility genes in men with aggressive disease: significant evidence for linkage at chromosome 15q12. Hum Genet (2006) 0.96
A new association test to test multiple-marker association. Genet Epidemiol (2009) 0.95
Dense genome-wide SNP linkage scan in 301 hereditary prostate cancer families identifies multiple regions with suggestive evidence for linkage. Hum Mol Genet (2009) 0.94
Molecular pathways in prostate cancer. Nephrourol Mon (2013) 0.92
Evolutionary conservation and expression of human RNA-binding proteins and their role in human genetic disease. Adv Exp Med Biol (2014) 0.92
Inhibition of HIV-1 gene expression by retroviral vector-mediated small-guide RNAs that direct specific RNA cleavage by tRNase ZL. Nucleic Acids Res (2005) 0.92
Association of HPC2/ELAC2 and RNASEL non-synonymous variants with prostate cancer risk in African American familial and sporadic cases. Prostate (2008) 0.91
Sequencing and analysis of a South Asian-Indian personal genome. BMC Genomics (2012) 0.91
Zinc- and iron-dependent cytosolic metallo-beta-lactamase domain proteins exhibit similar zinc-binding affinities, independent of an atypical glutamate at the metal-binding site. Biochem J (2005) 0.91
Pathogenesis-related mutations in the T-loops of human mitochondrial tRNAs affect 3' end processing and tRNA structure. RNA Biol (2012) 0.90
Evidence for a heritable predisposition to Chronic Fatigue Syndrome. BMC Neurol (2011) 0.90
ELAC2 polymorphisms and prostate cancer risk: a meta-analysis based on 18 case-control studies. Prostate Cancer Prostatic Dis (2010) 0.89
HPC2/ELAC2 polymorphisms and prostate cancer risk: analysis by age of onset of disease. Br J Cancer (2002) 0.89
Identification of a prostate cancer susceptibility locus on chromosome 7q11-21 in Jewish families. Proc Natl Acad Sci U S A (2004) 0.89
Genetic ancestry, self-reported race and ethnicity in African Americans and European Americans in the PCaP cohort. PLoS One (2012) 0.89
Residues in two homology blocks on the amino side of the tRNase Z His domain contribute unexpectedly to pre-tRNA 3' end processing. RNA (2006) 0.88
Prostate cancer susceptibility loci: finding the genes. Adv Exp Med Biol (2008) 0.87
A recurrent truncating germline mutation in the BRIP1/FANCJ gene and susceptibility to prostate cancer. Br J Cancer (2009) 0.87
Genetic susceptibility to prostate cancer in men of African descent: implications for global disparities in incidence and outcomes. Can J Urol (2008) 0.86
GeneLink: a database to facilitate genetic studies of complex traits. BMC Genomics (2004) 0.86
Krüppel cripples prostate cancer: KLF6 progress and prospects. Am J Pathol (2003) 0.86
A novel 4-base-recognizing RNA cutter that can remove the single 3' terminal nucleotides from RNA molecules. Nucleic Acids Res (2004) 0.86
PALB2 variants in hereditary and unselected Finnish prostate cancer cases. J Negat Results Biomed (2009) 0.86
tRNase Z catalysis and conserved residues on the carboxy side of the His cluster. Biochemistry (2007) 0.85
Identification by Mn2+ rescue of two residues essential for the proton transfer of tRNase Z catalysis. Nucleic Acids Res (2006) 0.85
The structure of the flexible arm of Thermotoga maritima tRNase Z differs from those of homologous enzymes. Acta Crystallogr Sect F Struct Biol Cryst Commun (2007) 0.85
Developmental roles of Drosophila tRNA processing endonuclease RNase ZL as revealed with a conditional rescue system. Dev Biol (2013) 0.85
Segregation analysis of 1,546 prostate cancer families in Finland shows recessive inheritance. Hum Genet (2007) 0.84
Sequence variants of elaC homolog 2 (Escherichia coli) (ELAC2) gene and susceptibility to prostate cancer in the Health Professionals Follow-Up Study. Carcinogenesis (2008) 0.83
Confirmation of the HPCX prostate cancer predisposition locus in large Utah prostate cancer pedigrees. Hum Genet (2004) 0.83
Effect of changes in the flexible arm on tRNase Z processing kinetics. J Biol Chem (2009) 0.83
Analysis of the RNASEL/HPC1, and macrophage scavenger receptor 1 in Asian-Indian advanced prostate cancer. Urology (2008) 0.83
A population-based analysis of clustering identifies a strong genetic contribution to lethal prostate cancer. Front Genet (2013) 0.83
Hereditary prostate cancer in Finland: fine-mapping validates 3p26 as a major predisposition locus. Hum Genet (2004) 0.82
tRNA 3' processing in yeast involves tRNase Z, Rex1, and Rrp6. RNA (2013) 0.82
A survey of green plant tRNA 3'-end processing enzyme tRNase Zs, homologs of the candidate prostate cancer susceptibility protein ELAC2. BMC Evol Biol (2011) 0.82
The genome sequence of Drosophila melanogaster. Science (2000) 74.32
The Ensembl genome database project. Nucleic Acids Res (2002) 40.87
A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science (1994) 36.53
Gene-expression profiles in hereditary breast cancer. N Engl J Med (2001) 29.80
Ensembl 2009. Nucleic Acids Res (2008) 25.38
Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest (2001) 23.21
Why are doctors so unhappy? There are probably many causes, some of them deep. BMJ (2001) 22.59
Evidence based medicine. BMJ (1995) 21.24
Ensembl 2008. Nucleic Acids Res (2007) 20.67
SGD: Saccharomyces Genome Database. Nucleic Acids Res (1998) 20.26
Ensembl 2007. Nucleic Acids Res (2006) 20.10
Integrating functional genomic information into the Saccharomyces genome database. Nucleic Acids Res (2000) 18.52
Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell (1991) 17.00
What clinical information do doctors need? BMJ (1996) 16.23
Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat Genet (1996) 15.73
Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature (2000) 15.53
Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet (1997) 15.38
Ensembl 2005. Nucleic Acids Res (2005) 15.13
Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet (1998) 15.09
Three-dimensional structure of myosin subfragment-1: a molecular motor. Science (1993) 14.90
The genome sequence of Schizosaccharomyces pombe. Nature (2002) 14.26
Informed consent: the intricacies. BMJ (1997) 13.97
Using the Saccharomyces Genome Database (SGD) for analysis of protein similarities and structure. Nucleic Acids Res (1999) 13.65
A cell cycle regulator potentially involved in genesis of many tumor types. Science (1994) 13.00
Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy (2008) 12.35
Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox. Cell (1991) 12.27
Ensembl 2002: accommodating comparative genomics. Nucleic Acids Res (2003) 12.26
Ensembl 2004. Nucleic Acids Res (2004) 11.88
Ensembl 2006. Nucleic Acids Res (2006) 11.66
Expression profiling using cDNA microarrays. Nat Genet (1999) 11.58
Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature (1999) 10.97
The DNA sequence of human chromosome 21. Nature (2000) 10.66
Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knock-outs using Cre recombinase. J Biol Chem (1999) 10.14
CRACM1 is a plasma membrane protein essential for store-operated Ca2+ entry. Science (2006) 9.61
Establishment of multiple sublineages of H5N1 influenza virus in Asia: implications for pandemic control. Proc Natl Acad Sci U S A (2006) 9.26
An ethical code for everybody in health care. BMJ (1998) 9.13
All changed, changed utterly. British medicine will be transformed by the Bristol case. BMJ (1998) 9.08
The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues. Mol Cell (2000) 8.95
Change in direction of flagellar rotation is the basis of the chemotactic response in Escherichia coli. Nature (1974) 8.95
Growing pressure on BMJ's obituaries. BMJ (1995) 8.92
Authorship: time for a paradigm shift? BMJ (1997) 8.90
A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med (1991) 8.65
Data management and analysis for gene expression arrays. Nat Genet (1998) 8.60
The failings of NICE. BMJ (2000) 8.50
Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res (2001) 8.34
Ratio-based decisions and the quantitative analysis of cDNA microarray images. J Biomed Opt (1997) 8.32
The future of medicine. BMJ (1994) 8.14
A good death. An important aim for health services and for us all. BMJ (2000) 8.03
Using evidence to inform health policy: case study. BMJ (2001) 7.99
Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet (1999) 7.72
Time to face up to research misconduct. BMJ (1996) 7.66
Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science (2001) 7.66
Beyond conflict of interest. Transparency is the key. BMJ (1998) 7.63
The genome of the natural genetic engineer Agrobacterium tumefaciens C58. Science (2001) 6.90
BRCA1 mutations in primary breast and ovarian carcinomas. Science (1994) 6.81
Kaposi's sarcoma-associated herpesvirus infects endothelial and spindle cells. Nat Med (1995) 6.71
MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene (2007) 6.55
The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet (1996) 6.43
Binding of c-Myc to chromatin mediates mitogen-induced acetylation of histone H4 and gene activation. Genes Dev (2001) 6.36
Meeting the information needs of health workers in developing countries. BMJ (1997) 6.31
Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet (2007) 6.29
Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst (1994) 6.27
Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science (1997) 6.23
Methylation of a membrane protein involved in bacterial chemotaxis. Proc Natl Acad Sci U S A (1975) 6.14
Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst (1998) 6.06
Positive and negative regulation of IkappaB kinase activity through IKKbeta subunit phosphorylation. Science (1999) 5.95
Medicine's core values. BMJ (1994) 5.93
Revel in electronic and paper media. BMJ (2000) 5.82
How well do patients take oral penicillin? A collaborative study in private practice. Pediatrics (1967) 5.82
A malaria model tested in the African savannah. Bull World Health Organ (1974) 5.74
Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology (2006) 5.67
Sp1 elements protect a CpG island from de novo methylation. Nature (1994) 5.60
The GMC on performance. BMJ (1992) 5.57
Informed consent: edging forwards (and backwards) BMJ (1998) 5.52
PubMed Central: creating an Aladdin's cave of ideas. BMJ (2001) 5.49
Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc Natl Acad Sci U S A (2001) 5.48
Does Britain need an academy of medicine? BMJ (1996) 5.47
Effect of open peer review on quality of reviews and on reviewers' recommendations: a randomised trial. BMJ (1999) 5.45
CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia. Nature (1997) 5.45
Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer (2001) 5.36
Disruption of the p70(s6k)/p85(s6k) gene reveals a small mouse phenotype and a new functional S6 kinase. EMBO J (1998) 5.34
Rationing: the search for sunlight. BMJ (1992) 5.26